glp-1 agonist adverse effects GI of Glucagon-Like Peptide-1 Receptor Agonists Glucagon-Like Peptide-1 Receptor Agonists in
Description
doi: 10.1001/jamasurg.2016.2317 5 Sanchez-GarridoMABrandtSJClemmensenCMullerTDDiMarchiRDTschopMH
The risk of cholelithiasis among different GLP1-RAs Table 4 showed the overall relative risk of cholelithiasis was 1.2, 1.3, and 1.4 in liraglutide, dulaglutide, and semaglutide versus control with number needed to harm of 17.25, 14.69, and 10.96, respectively
10.1056/NEJMoa1307684
Trends Mol
Final Thoughts The approval of Wegovy for certain adults with MASH and moderate-to-advanced fibrosis is an important development in metabolic medicine
[26], and Adeniran et al
